Skip to the page content
Your donations
Passes our checks

Cancer Research Institute Inc

EIN 13-1837442 · New York, NY

Public records show a registered, tax-exempt organization in good standing.

LegitimacyPassesRegistration and standingFinancial healthGood75 out of 100GovernanceStrong100 out of 100Impact evidenceDescribes programsHow well its results are evidenced

What it says it does

SEE SCHEDULE OCRI IS A NONPROFIT ORGANIZATION DEDICATED TO ADVANCING CANCER IMMUNOTHERAPY THROUGH SCIENTIFIC DISCOVERY AND GLOBAL COLLABORATION. SINCE 1953, CRI HAS FUNDED RESEARCH THAT DEEPENS UNDERSTANDING OF THE IMMUNE SYSTEM AND ITS ROLE IN CANCER, LEADING TO BREAKTHROUGHS SUCH AS CHECKPOINT BLOCKADE AND CELL-BASED THERAPIES. THROUGH INVESTMENTS IN SCIENCE, DATA, AND THE RESEARCH COMMUNITY, CRI WORKS TO TRANSLATE DISCOVERIES INTO EFFECTIVE TREATMENTS FOR PATIENTS.

Income
$35.5 million
Spending
$42.1 million
Spent on programs
79%
Reserves
20 months of spending
Largest source of income
donations and private grants, 75%
Employees
31
Volunteers
130
Highest pay
$747,735, former ceo (thru 8/2024)

Source: Form 990 for the year ending June 30, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Financial health

Good: 75 out of 100. Higher than 50% of charities in its peer group (medical research, $10m to $100m).

  • Reserves

    35 of 35

    Spendable reserves would cover 20.0 months of spending.

  • Debt

    10 of 20

    It owes 35% of what it owns.

  • Living within its means

    0 of 15

    Spending exceeded income by 19% of income.

  • Income trend

    15 of 15

    Income rose 48% on the year before.

  • Spending floor

    15 of 15

    79% of spending went to programs and raising each dollar of donations cost 18 cents.

Source: Form 990 for the year ending June 30, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Governance

Strong: 100 out of 100. Higher than 45% of charities in its peer group (medical research, $10m to $100m).

  • Independent board

    25 of 25

    33 of 33 voting board members are independent.

  • Conflict of interest policy

    15 of 15

    Has a written conflict of interest policy.

  • Whistleblower policy

    8 of 8

    Has a written whistleblower policy.

  • Record keeping policy

    7 of 7

    Has a written policy on keeping and destroying records.

  • Board minutes

    5 of 5

    Keeps minutes of board meetings.

  • Board sees the tax return

    10 of 10

    Gave the board a copy of this return before filing it.

  • Pay set independently

    5 of 5

    Sets its chief executive's pay through independent review and comparison.

  • Independent check of accounts

    15 of 15

    Its accounts were audited by an independent accountant.

  • No reported misuse

    10 of 10

    Reports no diversion of assets, excess benefits or loans to insiders.

Source: Form 990 for the year ending June 30, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Impact evidence

Describes programs. Its tax return describes what it does but we have found no measurable results in it.

Programs described in its return (4)
  1. $25.8 million spent. RESEARCH: CAREER DEVELOPMENT AWARDS + TRANSLATIONAL INNOVATION AND CLINICAL IMPACT AWARDS - SEE SCHEDULE OCRI SUPPORTS WORLD-CLASS SCIENTISTS ACROSS CAREER STAGES TO DRIVE DISCOVERY IN CANCER IMMUNOLOGY AND IMMUNOTHERAPY. CAREER DEVELOPMENT AWARDS, INCLUDING POSTDOCTORAL FELLOWSHIPS AND THE LLOYD J. OLD STAR PROGRAM, PROVIDE FLEXIBLE, MULTI-YEAR FUNDING TO EMERGING AND ESTABLISHED INVESTIGATORS PURSUING HIGH-IMPACT, INNOVATIVE RESEARCH. AWARDS RANGE FROM APPROXIMATELY $243,000 OVER THREE YEARS FOR FELLOWSHIPS TO $1.25 MILLION OVER FIVE YEARS FOR STARS. TRANSLATIONAL INNOVATION AND CLINICAL IMPACT AWARDS, INCLUDING CLIP (CLINIC AND LABORATORY INTEGRATION PROGRAM) GRANTS (UP TO $300,000 OVER TWO YEARS) AND TECHNOLOGY IMPACT AWARDS (UP TO $300,000 OVER TWO YEARS) SUPPORT PROJECTS THAT DEEPEN UNDERSTANDING OF TUMOR-IMMUNE INTERACTIONS AND ADVANCE NEW IMMUNOTHERAPEUTIC STRATEGIES TOWARD CLINICAL APPLICATION.
  2. $4.4 million spent. CLINICAL - SEE SCHEDULE OCRI ACCELERATES THE DEVELOPMENT OF PROMISING IMMUNOTHERAPIES THROUGH EARLY-PHASE CLINICAL RESEARCH AND COLLABORATIVE TRIALS. THE CLINICAL INNOVATOR PROGRAM SUPPORTS NOVEL CLINICAL STUDIES WITH FUNDING OF UP TO $1 MILLION PER TRIAL, WHILE THE CLINICAL ACCELERATOR IS AN ACTIVELY MANAGED VENTURE PHILANTHROPY PROGRAM THAT DESIGNS AND CONDUCTS DATA-DRIVEN, MULTI-PARTNER CLINICAL STUDIES IN AREAS OF HIGH UNMET NEED.
  3. $2.9 million spent. DATA - SEE SCHEDULE OCRI ADVANCES THE USE OF DATA TO ENABLE DISCOVERY, TRANSLATION, AND CROSS-STUDY LEARNING IN IMMUNOTHERAPY RESEARCH. THROUGH SUPPORT FOR DATA RESOURCES, ANALYTIC TOOLS, AND COMMUNITY GUIDANCE, CRI SUPPORTS INITIATIVES THAT IMPROVE DATA QUALITY, STANDARDIZATION, AND INTEROPERABILITY ACROSS THE FIELD. THESE EFFORTS HELP UNLOCK INSIGHTS INTO RESPONSE AND RESISTANCE AND GUIDE MORE EFFECTIVE DEVELOPMENT OF IMMUNOTHERAPIES.
  4. $290,903 spent. PATIENT & POLICY:CRI PROVIDES EDUCATION AND ENGAGEMENT TO IMPROVE PATIENT UNDERSTANDING OF IMMUNOTHERAPY AND SUPPORT INFORMED DECISION-MAKING. THROUGH DIGITAL CONTENT, EVENTS, AND MEDIA OUTREACH, CRI REACHES PATIENTS, CAREGIVERS, AND STAKEHOLDERS WITH ACCESSIBLE SCIENTIFIC AND MEDICAL INFORMATION, INCLUDING RESOURCES IN MULTIPLE LANGUAGES. CRI ALSO CONTRIBUTES TO FIELD-BUILDING BY CONVENING STAKEHOLDERS AND SUPPORTING EFFORTS THAT IMPROVE ACCESS TO AND DELIVERY OF IMMUNOTHERAPIES.

Source: Form 990 for the year ending June 30, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Legitimacy checks

  1. Is it registered with the IRS? Passed.

    Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  2. Has the IRS revoked its tax-exempt status? Passed.

    Not on the IRS automatic revocation list.

    Source: Automatic revocation of exemption list, Internal Revenue Service, file dated November 6, 2026.

  3. Are donations tax-deductible? Passed.

    On the IRS list of organizations eligible to receive tax-deductible contributions.

    Source: Publication 78 data: organizations eligible for tax-deductible contributions, Internal Revenue Service, file dated October 13, 2026.

  4. Is it keeping up with its IRS filings? Passed.

    Most recent return on file covers the year ending June 2025.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  5. How long has it been tax-exempt? Passed.

    Recognized by the IRS since November 1953.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  6. Is it in good standing with state regulators? Passed.

    Not on California's list of charities barred from soliciting. Other states are not yet checked.

    Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated November 4, 2026.

Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.